ArticleeLife2018
The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer.
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 87 citations in OpenAlex.
- Metabolic pathways fuelling devil facial tumour diseases.The FEBS journal · 2026Article
- Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers.The EMBO journal · 2026Article
- Immunological surveillance against cancer across mammals.Nature communications · 2025Article
- The devil in more detail: Eco-evolutionary genomics of Tasmanian devil persistence despite range-wide spread of a fatal, transmissible cancer.PLoS pathogens · 2025Article
- Pathologic and Therapeutic Schwann Cells.Cells · 2025Review
- Differentially expressed growth factors and cytokines drive phenotypic changes in transmissible cancers.Discovery immunology · 2025Article
- Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts.Nature biomedical engineering · 2024Article
- In vitro competition between two transmissible cancers and potential implications for their host, the Tasmanian devil.Evolutionary applications · 2024Article
- The evolution of two transmissible cancers in Tasmanian devils.Science (New York, N.Y.) · 2023Article
- Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours.Open biology · 2022Article
- Population genetics of clonally transmissible cancers.Nature ecology & evolution · 2022Review
- Expression of the Nonclassical MHC Class I, Saha-UD in the Transmissible Cancer Devil Facial Tumour Disease (DFTD).Pathogens (Basel, Switzerland) · 2022Article
- Genetic diversity and disease: The past, present, and future of an old idea.Evolution; international journal of organic evolution · 2022Article
- Challenges of an Emerging Disease: The Evolving Approach to Diagnosing Devil Facial Tumour Disease.Pathogens (Basel, Switzerland) · 2021Review
- Extracellular vesicle proteomes of two transmissible cancers of Tasmanian devils reveal tenascin-C as a serum-based differential diagnostic biomarker.Cellular and molecular life sciences : CMLS · 2021Article
- Between the Devil and the Deep Blue Sea: Non-Coding RNAs Associated with Transmissible Cancers in Tasmanian Devil, Domestic Dog and Bivalves.Non-coding RNA · 2021Article
- The differentiation state of the Schwann cell progenitor drives phenotypic variation between two contagious cancers.PLoS pathogens · 2021Article
- NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.Journal of cancer research and clinical oncology · 2021Article
- The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif.Immunology · 2021Article
- Group phenotypic composition in cancer.eLife · 2021Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Devil Facial Tumour 2 (DFT2) is a recently discovered contagious cancer circulating in the Tasmanian devil (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.